Follitropin delta is under clinical development by Ferring International Center and currently in Pre-Registration for Female Infertility. According to GlobalData, Pre-Registration drugs for Female Infertility have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Follitropin delta’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Follitropin delta overview
Follitropin delta (Rekovelle) is a recombinant follicle-stimulating hormone (rFSH) with ovarian stimulation activity. It is formulated as solution for subcutaneous route of administration. Rekovelle is indicated for controlled ovarian stimulation and for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
The drug candidate is under development for controlled ovarian stimulation in women undergoing an assisted reproductive technology programme and male infertility.
Ferring International Center overview
Ferring International Center (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility; FE 202767 for Lactation; RBX2660 enema for difficile infection among others. The company has 11 R&D centres in China, Brazil, India, Israel, Denmark, Japan, Switzerland, the UK and the US. Ferring is headquartered in Saint-Prex, Switzerland.
For a complete picture of Follitropin delta’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
